BBY vs ALNY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BBY · Best Buy$99.63 ▲ 0.23%
ALNY · Alnylam Pharmaceuticals$155.94 ▼ 0.46%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BBY +34.2%
- ALNY -64.7%
Head to head
| Metric | BBY | ALNY |
|---|---|---|
| Price | $99.63 | $155.94 |
| Change today | ▲ 0.23% | ▼ 0.46% |
| Market cap | $20.90B | $20.89B |
| Return, 3 months | +22.1% | -28.1% |
| Return, year to date | +54.7% | -60.8% |
| Return, 1 year | +32.7% | -64.8% |
| P/E (TTM) | 16.6 | 8.1 |
| P/B | 6.6 | 5.8 |
| P/E percentile vs own 5y | 81st | 80th |
| Dividend yield | 3.83% | – |
| Revenue growth (YoY, latest qtr) | +3.6% | +66.9% |
| Net profit growth (YoY) | +69.4% | +327.7% |
| Gross margin | 22.7% | 79.7% |
| Operating margin | 4.3% | 20.8% |
| Net margin | 3.0% | 16.1% |
| Return on equity | 43.1% | 96.6% |
| Analyst target vs. price | -9.8% | +103.5% |
| Analyst buy share | 20% | 76% |
| RSI (14) | 59 | 22 |
| 30-day volatility | 44.2% | 90.9% |
| Max drawdown, 1 year | -32.0% | -67.6% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BBY is the largest of the group by market value.
- BBY has returned the most over the past year.
- ALNY carries the lowest trailing P/E.
- ALNY is growing revenue fastest.
- ALNY keeps the most profit per dollar of sales.
- BBY has been the calmest stock over the last 30 days.